Figitumumab has anti-tumor activity in Ewing's sarcoma
Wednesday, December 23, 2009 - 18:49
in Health & Medicine
A preliminary study of the anticancer drug figitumumab has found that it has antitumour activity in Ewing's sarcoma -a cancer which affects mainly teenage boys. The results have led to the drug's progression to a Phase 2 trial in patients with Ewing's sarcoma, which has recently finished recruiting. These are the conclusions of an Article published Online First in the Lancet Oncology. The study is by Dr Johann S de Bono, The Institute for Cancer Research (ICR), Sutton, UK, and The Royal Marsden NHS Foundation Trust, Sutton, UK, and colleagues.